High expression of Sam68 in sacral chordomas is associated with worse clinical outcomes
- PMID: 29026317
- PMCID: PMC5626414
- DOI: 10.2147/OTT.S147446
High expression of Sam68 in sacral chordomas is associated with worse clinical outcomes
Abstract
Src-associated in mitosis of 68 kDa (Sam68), also known as KHDRBS1 (KH domain-containing, RNA-binding, signal transduction-associated 1), is a member of the signal transduction and activation of RNA family. Previous studies have demonstrated that the aberrant expression of Sam68 is associated with the progression and prognosis of a variety of cancers, but little is known about its expression and role in chordomas, which are rare and aggressive bone neoplasms. In this study, we analyzed 40 tumor tissues and 20 distant normal tissues obtained from 40 patients with sacral chordoma using immunohistochemistry, and observed the expression of Sam68 was significantly upregulated in sacral chordomas compared with normal tissues (P=0.001). A positive correlation between the expression of Sam68 and the cell proliferation index Ki-67 was determined using Spearman's rank correlation test (γ =0.599, P<0.001). In addition, high expression of Sam68 was significantly associated with surrounding muscle invasion (P<0.001). Moreover, Kaplan-Meier curves showed that patients with overexpressed Sam68 had shorter local recurrence-free survival time (P<0.001). Lastly, multivariate analysis indicated that Sam68 is an independent prognostic factor for the local recurrence-free survival of sacral chordomas (hazard ratio =5.929, 95% CI: 1.092-32.188, P=0.039). Our findings suggest the use of Sam68 as a predictor for the recurrence of sacral chordomas.
Keywords: Sam68; prognostic factor; recurrence; sacral chordoma.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures




Similar articles
-
Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.Biochem Biophys Res Commun. 2017 Sep 30;491(4):1047-1054. doi: 10.1016/j.bbrc.2017.08.008. Epub 2017 Aug 3. Biochem Biophys Res Commun. 2017. PMID: 28780352
-
The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.J Mol Histol. 2015 Dec;46(6):485-97. doi: 10.1007/s10735-015-9639-y. Epub 2015 Oct 5. J Mol Histol. 2015. PMID: 26438629
-
Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.J Neurooncol. 2014 Jan;116(1):77-82. doi: 10.1007/s11060-013-1274-4. Epub 2013 Oct 18. J Neurooncol. 2014. PMID: 24135846
-
Local and Distant Recurrence in Resected Sacral Chordomas: A Systematic Review and Pooled Cohort Analysis.Global Spine J. 2019 Apr;9(2):191-201. doi: 10.1177/2192568217741114. Epub 2018 May 30. Global Spine J. 2019. PMID: 30984500 Free PMC article. Review.
-
[Chordoma].Neurochirurgie. 2014 Jun;60(3):63-140. doi: 10.1016/j.neuchi.2014.02.003. Epub 2014 May 23. Neurochirurgie. 2014. PMID: 24856008 Review. French.
Cited by
-
Role of Sam68 in different types of cancer (Review).Int J Mol Med. 2025 Jan;55(1):3. doi: 10.3892/ijmm.2024.5444. Epub 2024 Oct 25. Int J Mol Med. 2025. PMID: 39450529 Free PMC article. Review.
-
Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.Front Oncol. 2022 Sep 29;12:997506. doi: 10.3389/fonc.2022.997506. eCollection 2022. Front Oncol. 2022. PMID: 36248987 Free PMC article.
-
RNA-binding proteins in bone pathophysiology.Front Cell Dev Biol. 2024 Jun 20;12:1412268. doi: 10.3389/fcell.2024.1412268. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38966428 Free PMC article. Review.
-
A giant lumbar chordoma: A case report.Medicine (Baltimore). 2018 Jun;97(25):e11128. doi: 10.1097/MD.0000000000011128. Medicine (Baltimore). 2018. PMID: 29924012 Free PMC article.
References
-
- Stiller CA, Trama A, Serraino D, et al. RARECARE Working Group Descriptive epidemiology of sarcomas in Europe: report from the RARE-CARE project. Eur J Cancer. 2013;49(3):684–695. - PubMed
-
- Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19(4):367–370. - PubMed
-
- McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12(1):1–11. - PubMed
-
- Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69–e76. - PubMed
-
- Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12(11):1344–1350. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous